Clinical trials: Gleason Score
Prostate Cancer
Prostate Cancer Upgrading Reference Set
Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence…
- Trial name
- NCT02189486
- Where
- United States
- Volunteers
- 382 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer, Radiation Therapy
Adjuvant Chemotherapy for High Malignant Prostate Cancer
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer.
- Conditions
- Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
- Trial name
- PKUFH-GS5 (NCT06864533)
- Testing
- Docetaxel
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies
Background: Prostate cancer is one of the most common cancers in men. For some men, their cancer is monitored. Others have surgery to remove the prostate. Focal therapy is another treatment option.
- Trial name
- NCT04541030
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Radiation Toxicity
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients…
- Trial name
- NCT00769223
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 3,561 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer
Prostate cancer is the second leading cause of cancer death in North American men older than 50 years. Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate…
- Trial name
- NCT02796807
- Testing
- 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods.
- Trial name
- NCT04808427
- Testing
- TULSA-PRO
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer
Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a…
- Trial name
- NCT00108290
- Testing
- Chemotherapy
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Prostate Cancer
Retrospective Study of Positive Biopsy Specimens on Patients Undergoing a Prostatectomy
This is a review of prostate biopsy specimens which show capsular penetration or positive surgical margins. Patients had surgery performed at William Beaumont Hospital-Royal Oak, Michigan.
- Trial name
- NCT00513721
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Corewell Health East
Prostate Cancer
Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer
Validate a non-DRE exosome gene expression test, with an NPV >/= 90% certainty, will exclude the presence of high gleason grade/ score (>/=7) prostate cancer in a prostate needle biopsy.
- Trial name
- NCT02702856
- Testing
- ExoIntelliScore Prostate
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer
MDPK67b in Patients With Prostate Cancer
Administration of MDPK67b to assess its Tolerability and Safety profile in prostate cancer patients, and to assess histo-pathological and molecular changes in prostate tumor tissue samples.
- Trial name
- NCT05580107
- Testing
- MDPK67b
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Med Discovery SA
Prostate Cancer
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored.
- Trial name
- NCT04692675
- Testing
- mpMRI
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer
This study involves Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy (removal of the prostate). SBRT is a relatively new radiation technique in which a few doses of radiation are delivered to small…
- Trial name
- NCT03748719
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Confined Adenocarcinoma of the Prostate
Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy
This will be a phase I study. This phase I study is not a standard drug dose escalation study, but rather a Clinical System Performance Evaluation Trial of a therapeutic device.
- Trial name
- NCT00426959
- Testing
- Image Guided Dynamic Dosimetry
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer.
- Trial name
- NCT03001895
- Testing
- 18F-DCFPyL PET/CT
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with…
- Trial name
- PCS III (NCT00223145)
- Testing
- Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Abdenour Nabid
Prostate Cancer
Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers
The objective of this study is to use as a reference the 36-month duration of hormonal therapy according to the European Organization for Research of the Treatment of Cancer (EORTC protocol 22863) : namely one-month of total…
- Trial name
- PCS IV (NCT00223171)
- Testing
- Androgen blockade + radiation therapy
- Where
- Canada
- Volunteers
- 630 people
- Sponsor
- Université de Sherbrooke
Prostate Cancer, Gleason Score
Dual-tracer PET Radiomics for Prostate Cancer Stratification
This single-center retrospective study aims to develop an interpretable radiomics model based on dual-tracer PET/CT to preoperatively predict the postoperative pathological Gleason grade group in treatment-naïve prostate cancer…
- Conditions
- Prostate Cancer, Gleason Score, PET/CT, Radiomics
- Trial name
- NCT07655648
- Testing
- PET/CT with Gallium-68 labeled PSMA and RM26
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancer
Post-operative or Early Salvage XRT and ADT for High Risk PCa
RATIONALE: Conformal radiation therapy uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor.
- Trial name
- NCT00949962
- Testing
- antiandrogen therapy, leuprolide acetate, 3-dimensional conformal radiation therapy
- Where
- France
- Volunteers
- 87 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand